A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

scientific article published in August 2002

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID12180720

P2093author name stringChristopher R Lines
Barry J Gertz
David R Mandel
David Borenstein
Sean Curtis
Agustin Melian
Harris H McIlwain
Alan K Matsumoto
Etoricoxib Rheumatoid Arthritis Study Group
Peng Liang Zhao
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectrheumatoid arthritisQ187255
P304page(s)1623-1630
P577publication date2002-08-01
P1433published inThe Journal of RheumatologyQ7743623
P1476titleA randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis
P478volume29

Reverse relations

cites work (P2860)
Q24794291A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
Q24615651A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity
Q24796193COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients
Q34847583Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib
Q34713083Clinical use and pharmacological properties of selective COX-2 inhibitors
Q38262502Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs
Q36861909Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
Q24796005Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
Q44971339Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Q38993297Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses
Q91639695Erratum to "Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac"
Q35016968Etoricoxib
Q35166773Etoricoxib for arthritis and pain management
Q34610283Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis
Q36098013Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial
Q48269682Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis
Q36013803Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Q42695576Pivotal factors for successful withdrawal of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis patients in remission or with low-disease activity
Q37893966Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
Q35028375The second generation of COX-2 inhibitors: what advantages do the newest offer?

Search more.